Home
About
About Anagenics
Board of Directors
Divisions
Our Divisions
Beauty
Brands
évolis®
Uspa
Investors
Investor Centre
ASX Announcements
2025
2024
2023
2022
2021
2020
Financial Information & Reports
Share Registry Information
Analyst Coverage
Share Information
Anagenics in the media
Newsletter Archive
Corporate Governance
Corporate Governance
Board Charter
Code of Conduct
Policies
Audit Committee Charter
Nomination and Remuneration Committee Charter
Performance Evaluation Process
Corporate Code of Conduct
Environmental, Social and Governance Statement
✕
2024
Home
2024
September 3, 2024
Published by
Dominic Burg
on
September 3, 2024
Categories
Pause in Trading
September 3, 2024
Published by
Dominic Burg
on
September 3, 2024
Categories
FY24 4E Presentation
September 3, 2024
Published by
Dominic Burg
on
September 3, 2024
Categories
F24 Appendix 4E and Preliminary Final Report
July 24, 2024
Published by
Dominic Burg
on
July 24, 2024
Categories
Appendix 4C Cash Flow & Activities Report
July 24, 2024
Published by
Dominic Burg
on
July 24, 2024
Categories
AN1 – Company Update Licence Partnership Announcement
July 1, 2024
Published by
Dominic Burg
on
July 1, 2024
Categories
Confirmation of Release – AN1 – Lapse of unlisted options
June 13, 2024
Published by
Dominic Burg
on
June 13, 2024
Categories
Change of Company Secretary
June 12, 2024
Published by
Dominic Burg
on
June 12, 2024
Categories
Midkine Antibody Licensing Deal
May 20, 2024
Published by
Dominic Burg
on
May 20, 2024
Categories
Response to Appendix 3Y Query
Prev page
1
2
3
4
5
6
Next page
